NCT04528329

Anosmia and / or Ageusia and Early Corticosteroid Use

Anosmia and / or Ageusia in COVID-19: Timeline, Treatment With Early Corticosteroid and Recovery

• Status: Unknown
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 300 (estimated)
• Sponsor: ClinAmygate · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Time to recover of Anosmia and / or ageusia and early corticosteroid use

Detailed description

In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4 mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the half-life after oral administration was approximately 7 hours, and after intravenous administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%). However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h compared with 18-36 h for prednisolone. Time to recover of Anosmia and / or ageusia and early corticosteroid use

Conditions

• Covid19
• Anosmia

Interventions

Type	Name	Description
DRUG	Early-Dexamethasone	early use of dexamethasone as early as laboratory evidence of high inflammatory markers
DRUG	Late dexamethazone	Use of dexamethasone on deterioration of the cases with increased severity

Timeline

• Start date: 2021-03-30
• Primary completion: 2023-11-01
• Completion: 2023-12-30
• First posted: 2020-08-27
• Last updated: 2023-09-06

Locations

1 site across 1 country: Egypt